If you have the choice of more than one vaccine and are wondering which one to take and how to assess the risk of side effects, this episode of Science in 5 with WHO’s Dr Katherine O’Brien is for you.
If you are caring for yourself or a loved one at home, how can you keep everyone safe? Who should be cared for at home? How to prevent COVID-19 infection to other family members? What red flags should you look for that tell you it is time to contact the health care provider? WHO’s Dr April Baller ...explains in Science in 5.
more
If you have COVID-19 and are caring for someone or yourself at home, what is the treatment protocol? What is WHO’s guidance on Remdesivir and convalescent plasma therapy? How to monitor oxygen at home and what are the red flags when you should call the doctor? WHO’s Dr Janet Diaz explains in Sci...ence in 5.
more
What are the variants circulating at this time? How are variants classified as variants of interest or concern? What does this mean for the public? Dr Maria Van Kerkhove explains in Science in 5 this week.
How does SARS-CoV-2 , the virus that causes COVID-19 , spread from one person to another? How can you keep yourself safe indoors and outdoors? WHO’s Dr Oliver Morgan explains in Science in 5.
What is the guidance for vaccination of women with breastfeeding infants, women who are pregnant or planning to get pregnant and women who are menstruating? What about vaccines and fertility? WHO’s Dr Soumya Swaminathan explains in Science in 5.
This protocol establishes the principles and definitions of a surveillance system devised by the WHO Health in Prisons Programme (HIPP) to monitor the evolution of COVID-19-related epidemiological data in prisons and other places of detention and to report the main measures adopted to prevent,... control and manage the spread of the disease.
more
Why does WHO recommend at this time, in June 2021, that vaccinating children is not a priority? When would their vaccination be prioritized? How is safety of these vaccines ensured? WHO’s Chief Scientist Dr Soumya Swaminathan explains in Science in 5.
This publication was developed in response to the need for a reference list of priority medical devices required for management of noncommunicable diseases (NCDs), focusing on cardiovascular diseases and diabetes, especially for low- and middle-income countries to support universal health coverage a...ctions.
more
This publication is based on the list of clinical interventions selected from clinical guidelines on prevention, screening, diagnosis, treatment, palliative care, monitoring and end of life care. This publication addresses medical devices for six types of cancer: breast, cervical, colorectal, leukem...ia, lung and prostate. The first section defines the global increase in cancer cases, the global goals to manage NCDs and the WHO activities related to these goals. The second section presents the methodology used for the selection of medical devices that support clinical interventions required to screen, diagnose, treat and monitor cancer stages, as well as the provision of palliative care, based on evidence-based information. The third section lists the priority medical devices required to manage cancer in seven different units of health care services: 1. Vaccination, clinical assessment and endoscopy, 2. Medical imaging and nuclear medicine, 3. Surgery, 4. Laboratory and pathology, 5. Radiotherapy, 6. Systemic therapy and 7. Palliative and end of life care
more
2nd edition, July 2021. This WHO and HRP guideline is designed to help countries make faster progress, more equitably, on the screening and treatment of cervical cancer. It includes some important shifts in WHO’s recommended approaches to cervical screening, and includes a total of 23 recommendati...ons and 7 good practice statements.
Among the 23 recommendations, 6 are identical for both the general population of women and for women living with HIV and 12 are different and specific for each population.
Among the 7 good practice statements, 3 are identical for both the general population of women and for women living with HIV and 2 are different and specific for each population
more
6 July 2021. The “WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis - Rapid diagnostics for tuberculosis detection 2021 update” is the latest document replacing the one issued in 2020. Three new nucleic acid amplification test (NAAT) classes are endorsed by WHO and included in the... latest consolidated guideline
more
What do we know about the Delta variant so far? How can we assess our risk? What strategies should we apply to protect ourselves whether we are in a low vaccination or high vaccination setting? WHO’s Dr Maria Van Kerkhove explains in Science in 5.
Globally, 311,000 women die of cervical cancer every year, 85 percent of them
in resource limited regions of the world. To address this grave threat to women,
the WHO made a call to action in 2018, resulting in accelerated plans to improve
cervical cancer control under the elimination threshold w...ith respect to cervical
cancer incidence. As part of WHO’s approach to cervical cancer control, availability of high quality,
affordable medical devices for HPV screening, and treatment of precancerous
lesions in low resource settings is indispensable.
more
The primary audience for this guidance is persons
working directly in vector-borne disease prevention
and control, including programme managers,
researchers and field workers. A brief technical
background is provided for the benefit of persons
without expertise in vector-borne diseases; readers...
working in the field may wish to skip the background
section and begin with the discussion of ethical
issues and values in Chapter 3. The guidance cannot
offer universally applicable answers to the complex
ethical issues raised, nor can it provide a checklist of
issues that are necessarily relevant in all situations.
Rather, its goal is to help readers recognize aspects
of their work that raise significant ethical challenges
and to respond to these challenges in accordance
with internationally accepted values and norms.
more
Injection practices worldwide and especially in low- and middle-income countries (LMICs) include multiple, avoidable unsafe practices that ultimately lead to the large-scale transmission of bloodborne viruses among patients, health care providers and the community at large.